Postirradiation extraosseous osteogenic sarcomas are uncommon in the head and neck, despite the extensive use of high-dose radiation. It has been described as de novo radiation-induced neoplasm. We present a 73-year-old male who had been treated by radiotherapy for gingival cancer 7 years earlier and later developed extraosseous osteogenic sarcomas (EOSs) of the neck. Microscopically, the neck mass was composed with mesenchymal malignant cells with cartilaginous and osteogenic differentiation. Immunohistochemical stain demonstrated strong positivity of tumor cells for Snail, the one of major epithelial-mesenchymal transition (EMT) inducer. The E-cadherin expression was scarce, showing inverse relationship to Snail expression. Compared with previous squamous cell carcinoma (SCC) of the gingiva, the present EOS sample revealed the remained epithelial cells on cytokeratin immunohistochemistry, suggesting the tumor arise from the cells of epithelial origin. We have also reviewed the previous 6 cases of head and neck EOSs carefully. The clinicopathologic features of the unusual lesion suggest that it is an incomplete EMT of precedent epithelial malignancy rather than de novo pathology.
Ⅰ. Introduction
Extraosseous osteogenic sarcomas (EOSs) occur rarely, accounting for 1% of all soft tissue sarcomas and 4% of all osteogenic sarcomas [1] [2] [3] . EOSs are biologically highly malignant neoplasm with an average 5-year survival rate of 15.6%. The tumors usually present in patients over age 40, in contrast with the juvenile predilection for intraosseous osteogenic sarcomas.
The common anatomic sites of EOS are the lower extremities, thigh, and buttocks 4 . The head and neck are unusual sites of EOS, only six cases being reported in the literature [3] [4] [5] [6] [7] [8] . Apart from an uninformed case, four of the cases were primary lesions, the remaining case being associated with radiotherapy.
We here attempt to determine the pathogenesis in a patient of an unusual EOS lesion that developed in the soft tissue of the neck after ablative surgery and radiotherapy for oral squamous cell carcinoma (SCC).
Ⅱ. Case report
A 66-year-old male initially presented with an unhealed extraction socket of three months duration. A series of examinations revealed gingival cancer with mandibular invasion. The patient underwent wide excision including segmental mandibulectomy with simultaneous functional neck dissection and reconstruction procedures with a pectoris major myocutaneous flap and reconstruction plates. Microscopically, the tumor was diagnosed as invasive squamous cell carcinoma arising from the gingiva with a metastatic lymph node (pT4N1M0). The mass produced adequate amounts of keratin, being thus regarded as moderately differentiated. (Fig. 1. A) The patient started radiotherapy 1 month after surgery, receiving the first week a dose of 4,500 cGy for the tumor bed and neck, boosted to 5,400 cGy the next one week. No particular findings were observed during the treatment period. Supplementary reconstructive surgery with an iliac bone graft was applied a year later due to a fatigue fracture of the reconstruction plate.
A second primary tumor mass was identified in the ipsilateral buccal mucosa 20 months after the initial surgery and completely excised. The specimen was an invasive squamous cell carcinoma, poorly differentiated. (Fig. 1. B) The postoperative course was uneventful until the left neck mass recurred 7 years and 9 months after the initial surgery.
Physical examination revealed a movable neck mass of about 3.0×3.0 cm with hard consistency. However, primary intraoral lesion associated with neck mass was not detected. A computed tomography scan showed a lowly attenuated mass with rim enhancement at the hyoid bone level of neck level III, bounded by the left sternocleidomastoid muscle posteriorly with left internal jugular vein anteromedially. (Fig. 2 ) Fine needle aspiration biopsy revealed a positive result for malignancy, and the lesion was diagnosed as a metastatic lymph node with necrotic center clinically originating from the oral cavity. Salvage neck node dissection was performed and the acquired specimen was submitted for histopathological evaluation.
Histologically, tumor mass surrounded by a fibrous capsule was noted, relatively well demarcated from adjacent tissues. The tumor was mainly composed of spindle-shaped cells exhibiting pleomorphism, hyperchromatism, and frequent mitosis, consistent with a malignant mesenchymal tumor. It contained deposits of hypercellular cartilage ( Fig. 1 . C) and aberrant osteoid. (Fig. 1 . D) There was no microscopic evidence that the region of the neck mass was lymph node, and the squamous differentiation noted in the previous oral cancer lesion could not be identified. The final diagnosis was extraosseous osteogenic sarcoma.
The immunohistochemical stains were done for both second primary SCC and EOS specimen samples by epithelial-mesenchymal transition (EMT)-associated antibody including cytokeratin, Snail, E-cadherin, and N-cadherin. Anti-cytokeratin AE1/3 (Dako, Carpinteria, USA), anti-E-cadherin (Invitrogen, Carlsbad, USA), and anti-N-cadherin (Invitrogen, South San Francisco, USA) were purchased. Polyclonal antiSnail1 antiserum was prepared as previously described 9, 10 . The SCC samples showed diffuse marked cytoplasmic cytokeratin expression and nuclear Snail expression in invasive front area. (Figs. 3. A, B) The expression of membranous E-cadherin was scarce, but remained. (Fig. 3. C) The N-cadherin expression could not be found. (Fig. 3 . D) In EOS sample, the presence of a tiny portion of epithelial tumor cells was proved by cytokeratin immunohistochemical staining. (Fig. 3. E) Snail was strongly expressed in the nucleus of entire mesenchymal tumor cells (Fig. 3. F) , but E-cadherin expression could not be found. (Fig. 3 . G) Some mesenchymal tumor cells showed membranous positivity for anti-N-cadherin, which was inverse relation to E-cadherin expression. (Fig. 3. H) 
Ⅲ. Analyses of head and neck EOSs
This is the seventh known case of head and neck EOS. (Table  1 ) Previously known anatomic sites of head and neck EOS include lip, chin, zygoma area, and parotid gland 5 . Excluded from these data was a 10-year-boy who developed osteogenic sarcoma in the soft tissue of the right orbit following radiotherapy for retinoblastoma 4, 11, 12 , later suggested to be of intraosseous origin 13 . Interestingly, the third case in Table 1 shares features with ours in its clinical course: the existence of SCC at primary sites, prolonged latency after radiotherapy, and development of EOS in a previously irradiated region. (Table 2) The biologic mechanism causing such unique clinicopathologic features remains obscure. It is unclear whether there are links between either radiotherapy or primary SCC and successive EOS lesions.
The EOS could occur de novo, and some of them resemble postirradiation sarcoma, a rare complication of radiotherapy 14 . Radiation induces sarcoma in 0.2% of patients who have undergone radiotherapy for over 5 years 15 . The chin lesion in the third case might have developed from non-neoplastic myositis ossificans into osteogenic sarcoma following repeated irradiation, and could thus be regarded as radiation-induced EOS. However, the relationship between EOS and previous carcinoma of multiple skin lesions remain to be explained.
The EOS could alternatively result from conversion into mesenchymal tumor of pre-existing epithelial malignancy. This might account for both cases in Table 2 . The EOS lesions occurred where epithelial cancer cells had previously presented, possible instances of irreversible transition to mesenchymal tumor of recurrent or metastatic SCC.
Ⅳ. Discussion
The EMT is a complex program whereby epithelial cells lose their polarity and cell-cell contacts and undergo a dramatic remodeling of the cytoskeleton with acquisition of mesenchymal expression components and manifestation of a migratory phenotype 16 . Down-regulation of E-cadherin function is well known to mark the initiation of the EMT. Snail family can act Although it is also well known that epithelial cancer cells can be reversibly or irreversibly converted into mesenchymal cells in vitro, EMT was until recently not recognized as a distinct process for cancer progression because 1) it cannot be traced in human tumor samples and 2) carcinomas and sarcomas are thought to interconvert 18 . Recently, pathological activation of the major EMT inducer, Snail, has been reported in a variety of primary tumors 19 . In epithelial tumors, Snail protein expression is restricted to dedifferentiated mesenchyme-like cancer cells and stromal cells placed at the invasive tumor front 20 . In our second primary SCC specimen samples, nuclear Snail expression was also noted in peripheral invasive front zone, in which there was no E-cadherin expression.
EMT may be a transient process that affects only a small fraction of the tumor cell population at any given time. The socalled "sarcomatoid carcinomas"represent a static feature of incomplete EMT with a mixed carcinoma/sarcoma appearance 18 . The majority of tumor cells in the present case showed mesenchymal phenotype and definitely strong Snail expression, with a few showing epithelial characteristics in immunohistochemical staining. These also reflect an incomplete EMT, on the basis of histopathological features.
The patient in the first case also had EOS of lower lip with precedence of SCC in the same region. The interval between the different tumors was more than 3 years, and the lesion was, interestingly, unrelated to radiotherapy 21 . These findings suggest that EMT could actually occur in vivo.
Metastatic carcinoma cells often show a redifferentiated epithelial phenotype [22] [23] [24] [25] . These results suggest that malignant progression, such as invasion and metastasis of cancer cells, might stem from a dynamic and transient EMT program, possibly regulated by epithelial-mesenchymal interactions in the microenvironment. As the two EOS lesions in Table 2 occurred in a previous irradiated region, it may be that radiation affects the tumor microenvironment and regulates EMT of pre-existing carcinoma cells. Though there is no reliable informed data on the prognosis of EOS following radiotherapy, it would likely be poorer than that for common recurrent head and neck cancer. Various treatment modalities should be considered with the patient, including resection followed by adjunct chemotherapy.
Better understanding of the mechanisms of carcinogenesis and EMT during cancer progression may clarify these exceptional in vivo phenomena, and also lead to the development of new targets for therapeutic intervention in cancer.
